6639 (6639) Fair Value & Analysis

Healthcare · Market cap HK$1.0B

6 6639 6639 · HK

PriceHK$1.83

Fair ValueHK$0.7100

Upside-61.2%

Quality51/100

Watch 6639 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.6500 – HK$0.9200

Fair value as of: Jul 2, 2026

From 23 valuation models · updated today

Price vs Fair Value (12 months)

12‑month range HK$1.59 – HK$2.88 · fair‑value band HK$0.6500 – HK$0.9200 · the HK$1.83 price screens above the HK$0.7100 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6639 (6639) currently trades at HK$1.83, while our model-based Fair Value estimate is HK$0.7100 — implying the stock looks roughly 61.2% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 6639 generated revenue of HK$1.7B at a net margin of 1.3%. Revenue declined 6.8% year over year. It earns a return on equity of 0.9%. Net debt stands at HK$491M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.7B

Revenue growth (YoY) -6.8%

Net margin 1.3%

Return on equity 0.9%

Free cash flow HK$173M FY2025

P/E ratio 30.5

More key figures

Operating margin 2.8%

EPS (TTM) HK$0.0300

EPS growth (YoY) +13.2%

Net debt HK$491M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6639 reported revenue of HK$1.7B in FY2025 versus HK$1.5B in FY2021, a compound +2.7%/yr. Reported net income was HK$22.0M in FY2025.

Revenue +2.7%/yr

FY21 HK$1.5B

FY22 HK$1.6B

FY23 HK$1.5B

FY24 HK$1.7B

FY25 HK$1.7B

Net income

FY21 −HK$599M

FY22 −HK$701M

FY23 −HK$220M

FY24 HK$17.2M

FY25 HK$22.0M

Is 6639 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.30	$8.61	-24%
5225 5225	8.67 MYR	3.08 MYR	-64%
IHHHF IHHHF	$1.71	$0.7400	-57%
Tenet Healthcare Corporation THC	$162.06	$282.55	+74%
Rede D'Or São Luiz S.A RDOR3	R$32.76	R$30.33	-7%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6639 (6639) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.7100 versus a price of HK$1.83 — about −61% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6639?

Our model-based fair value for 6639 is HK$0.7100 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.83.

What is the quality score of 6639?

6639 has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6639 (6639)?

6639 reported trailing-twelve-month revenue of about HK$1.7B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6639?

The net profit margin of 6639 is about 1.3%, meaning it keeps roughly 1.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.